Journal of Cancer Discovery: we are a part of the battlefield

Kai Huang

doi:10.55976/jcd.1202215913

Home /

Archives /

Journal of Cancer Discovery, Volume 1 Issue 1, 2022 /

Editorial

Journal of Cancer Discovery: we are a part of the battlefield

Kai Huang ¹ ^*

1. Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China

Correspondence: kaih91sdu@gmail.com

DOI: https://doi.org/10.55976/jcd.1202215913

Received

11 March 2022
Revised

13 March 2022
Accepted

14 March 2022
Published

16 March 2022

Abstract

The world has witnessed the tremendous development of anticancer therapies over the past decades. Our tools to fight against this ancient enemy have evolved from traditional chemotherapy to targeted therapy, and then to immunotherapy now. Especially with the great success of immune checkpoint blockade therapies such as anti-PD-1 antibodies, we have taken a giant leap towards the future in which cancer will no longer be seen as an irreparable tragedy of life.
However, we are still far from winning the battle against cancer. The current therapeutic strategies are not close to the final answer of cancer treatment, with limited PFS and OS with almost all the treatments in the majority of the patients and types of cancer. The game is still in the hard mode. That is how I feel when I see the clinical trial results reporting a few more weeks’ prolonged survival time, and doctors all over the world excited about it. Fundamentally, our understanding of the biological processes of cancer is still limited, and new discoveries and ideas are urgently needed to make breakthroughs.
The age of the universe is about 13.7 billion years. The Earth was born roughly 4.5 billion years ago. The first life on Earth appeared about 3.8 billion years ago. The first cancer was found on the fossil of a turtle living nearly 230 million years ago. The first human found to have cancer lived about 1.7 million years ago. The first anticancer drug, nitrogen mustard, was approved 65 years ago. I feel lucky that I live in an era with rapid progress in cancer research and clinical practice, and act as both a doctor in medical oncology and a scientific worker in the field of cancer research to play a part in the fight against this familiar opponent. That’s why we launched the Journal of Cancer Discovery (JCD): we want to be a part of the battlefield, and do our best to provide some new ideas for the human beings to win this billion-year-old battle. 
JCD is an open-access, peer-reviewed and bilingual journal. Like other Luminescience journals, in addition to publishing in English, our professional editing team will also provide the readers with abstracts in Chinese, and the full text of some selected manuscripts will be published in both English and Chinese. We also welcome authors to provide us with the abstract in their native language after the article is accepted. Our aim is to enhance global communication in cancer research, and to let different voices from all over the world be heard. We hope and believe that JCD will be an outstanding journal in cancer research in the near future.

Download PDF

Download XML

How to Cite

Huang, K. “Journal of Cancer Discovery: We Are a Part of the Battlefield”. Journal of Cancer Discovery, vol. 1, no. 1, Mar. 2022, p. 13, doi:10.55976/jcd.1202215913.

Download Citation

Issue

Journal of Cancer Discovery, Volume 1 Issue 1, 2022

Section

Editorial

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright licenses detail the rights for publication, distribution, and use of research. Open Access articles published by Luminescience do not require transfer of copyright, as the copyright remains with the author. In opting for open access, the author(s) should agree to publish the article under the CC BY license (Creative Commons Attribution 4.0 International License). The CC BY license allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license, users are free to share (copy, distribute and transmit) and remix (adapt) the contribution, including for commercial purposes, providing they attribute the contribution in the manner specified by the author or licensor.

Home /

Archives /

Journal of Cancer Discovery, Volume 1 Issue 1, 2022 /

Editorial

Journal of Cancer Discovery: we are a part of the battlefield

Abstract

How to Cite

Issue

Section

License

Follow Luminescience

Further Information

Home / Archives / Journal of Cancer Discovery, Volume 1 Issue 1, 2022 / Editorial

Journal of Cancer Discovery: we are a part of the battlefield

Abstract

How to Cite

Issue

Section

License

Follow Luminescience

Further Information

Home /

Archives /

Journal of Cancer Discovery, Volume 1 Issue 1, 2022 /

Editorial